These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1701055)

  • 1. Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors.
    Ashorn P; Moss B; Weinstein JN; Chaudhary VK; FitzGerald DJ; Pastan I; Berger EA
    Proc Natl Acad Sci U S A; 1990 Nov; 87(22):8889-93. PubMed ID: 1701055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-HIV effects of CD4-Pseudomonas exotoxin on human lymphocyte and monocyte/macrophage cell lines.
    Ashorn P; Moss B; Berger EA
    Ann N Y Acad Sci; 1990; 616():149-54. PubMed ID: 2078015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of CD4-Pseudomonas exotoxin against cells expressing diverse forms of the HIV and SIV envelope glycoproteins.
    Ashorn P; Moss B; Berger EA
    J Acquir Immune Defic Syndr (1988); 1992; 5(1):70-7. PubMed ID: 1738090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses.
    Berger EA; Clouse KA; Chaudhary VK; Chakrabarti S; FitzGerald DJ; Pastan I; Moss B
    Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9539-43. PubMed ID: 2480605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4-Pseudomonas exotoxin conjugates delay but do not fully inhibit human immunodeficiency virus replication in lymphocytes in vitro.
    Tsubota H; Winkler G; Meade HM; Jakubowski A; Thomas DW; Letvin NL
    J Clin Invest; 1990 Nov; 86(5):1684-9. PubMed ID: 2243139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages.
    Ashorn P; Englund G; Martin MA; Moss B; Berger EA
    J Infect Dis; 1991 Apr; 163(4):703-9. PubMed ID: 2010626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary HIV-1 isolates refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin.
    Kennedy PE; Moss B; Berger EA
    Virology; 1993 Jan; 192(1):375-9. PubMed ID: 8517027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CD4-PE40 is cytotoxic for a transfected mammalian cell line stably expressing the envelope protein of human immunodeficiency virus (HIV-1), and cytotoxicity is variably inhibited by the sera of HIV-1-infected patients.
    Pitts TW; Bohanon MJ; Leach MF; McQuade TJ; Marschke CK; Merritt JA; Wierenga W; Nicholas JA
    AIDS Res Hum Retroviruses; 1991 Sep; 7(9):741-50. PubMed ID: 1742081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant CD4-Pseudomonas exotoxin hybrid protein displays HIV-specific cytotoxicity without affecting MHC class II-dependent functions.
    Berger EA; Chaudhary VK; Clouse KA; Jaraquemada D; Nicholas JA; Rubino KL; Fitzgerald DJ; Pastan I; Moss B
    AIDS Res Hum Retroviruses; 1990 Jun; 6(6):795-804. PubMed ID: 2114147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of a genetic immunotoxin to eliminate toxin immunogenicity.
    Chen SY; Zani C; Khouri Y; Marasco WA
    Gene Ther; 1995 Mar; 2(2):116-23. PubMed ID: 7719928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus.
    Davey RT; Boenning CM; Herpin BR; Batts DH; Metcalf JA; Wathen L; Cox SR; Polis MA; Kovacs JA; Falloon J
    J Infect Dis; 1994 Nov; 170(5):1180-8. PubMed ID: 7963711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons.
    Ramachandran RV; Katzenstein DA; Wood R; Batts DH; Merigan TC
    J Infect Dis; 1994 Oct; 170(4):1009-13. PubMed ID: 7930696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interdomain interactions in the chimeric protein toxin sCD4(178)-PE40: a differential scanning calorimetry (DSC) study.
    Davio SR; Kienle KM; Collins BE
    Pharm Res; 1995 May; 12(5):642-8. PubMed ID: 7479546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and enhanced cytotoxicity of a [cyanovirin-N]-[Pseudomonas exotoxin] conjugate against human immunodeficiency virus-infected cells.
    Mori T; Shoemaker RH; McMahon JB; Gulakowski RJ; Gustafson KR; Boyd MR
    Biochem Biophys Res Commun; 1997 Oct; 239(3):884-8. PubMed ID: 9367864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a soluble CD4 and CD4-Pseudomonas exotoxin A chimeric protein on human peripheral blood lymphocytes: lymphocyte activation and anti-HIV activity in vitro.
    Rubino KL; Tarpley WG; Nicholas JA
    Antiviral Res; 1991 Oct; 16(3):267-79. PubMed ID: 1805685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.
    Kreitman RJ; Chang CN; Hudson DV; Queen C; Bailon P; Pastan I
    Int J Cancer; 1994 Jun; 57(6):856-64. PubMed ID: 8206679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4-Pseudomonas exotoxin hybrid proteins: modulation of potency and therapeutic window through structural design and characterization of cell internalization.
    Winkler G; Jakubowski A; Turner S; Liu T; Burrus B; McGray P; Heanue T; Rosa M; Griffiths BA; Wali A
    AIDS Res Hum Retroviruses; 1991 Apr; 7(4):393-401. PubMed ID: 2069820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous presence of CD4-PE40 is required for antiviral activity against single-passage HIV isolates and infected peripheral blood mononuclear cells.
    Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1091-6. PubMed ID: 8312052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for the use of immunotoxins in the treatment of HIV-infected humans.
    Van Oijen MG; Preijers FW
    J Drug Target; 1998; 5(2):75-91. PubMed ID: 9588864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia.
    Kreitman RJ; Chaudhary VK; Waldmann T; Willingham MC; FitzGerald DJ; Pastan I
    Proc Natl Acad Sci U S A; 1990 Nov; 87(21):8291-5. PubMed ID: 2236041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.